Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

The chairman of the House of Representatives Committee on University Education, Abubakar Hassan Fulata, has dismissed allegations by an online medium that lawmakers demanded a certain amount of money ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

The Vice Chancellor of Federal University Gusau, Zamfara State, Prof Mu’azu Abubakar Gusau, has dismissed a media report ...

The NCAA and the attorneys general of Tennessee and Virginia agreed to settle an antitrust lawsuit brought by the states in ...

subject to the recipient’s continued service with the Company through the applicable vesting date. The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.

The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The option vests ...

The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement date of ...

Olema is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).